This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT01314118
Previous Study | Return to List | Next Study

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Janssen Biotech, Inc.
ClinicalTrials.gov Identifier:
NCT01314118
First received: March 4, 2011
Last updated: July 20, 2017
Last verified: July 2017
History of Changes
Results First Received: December 24, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Prostate Cancer
Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Abiraterone Acetate Participants were given Abiraterone Acetate 1000 milligram (mg) (4*250 mg) tablets and Prednisone 5 mg (2*2.5 mg) tablets orally once daily in Core Study Treatment Phase (comprised of 6, 28 day cycles). After the Core Study Treatment Phase, participants who entered the Pre-metastatic Disease Follow-up Phase continued the study treatment until radiographic confirmation of disease progression, intolerable toxicity, investigator’s decision, and withdrawal by participant or until the sponsor decided to stop the trial.

Participant Flow:   Overall Study
    Abiraterone Acetate
STARTED   131 
COMPLETED   0 
NOT COMPLETED   131 
Adverse Event                9 
Progressive disease                27 
Physician Decision                11 
Death                4 
Protocol Violation                5 
Withdrawal by Subject                11 
Unspecified                2 
Ongoing                62 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who received at least 1 dose of study drug.

Reporting Groups
  Description
Abiraterone Acetate Participants were given Abiraterone Acetate 1000 milligram (mg) (4*250 mg) tablets and Prednisone 5 mg (2*2.5 mg) tablets orally once daily in Core Study Treatment Phase (comprised of 6, 28 day cycles). After the Core Study Treatment Phase, participants who entered the Pre-metastatic Disease Follow-up Phase continued the study treatment until radiographic confirmation of disease progression, intolerable toxicity, investigator’s decision, and withdrawal by participant or until the sponsor decided to stop the trial.

Baseline Measures
   Abiraterone Acetate 
Overall Participants Analyzed 
[Units: Participants]
 		 131 
Age 
[Units: Years]
Mean (Standard Deviation) 		 71.2  (8.82) 
Sex: Female, Male 
[Units: Participants]
Count of Participants 		 
Female      0   0.0% 
Male      131 100.0% 
Region of Enrollment 
[Units: Participants]
 		 
USA   131 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study   [ Time Frame: End of core study visit (Approximately at Month 6) ]
  Show Outcome Measure 1

2.  Secondary:   Time to Radiographic Evidence of Disease Progression (TTRP)   [ Time Frame: Maximum up to Month 30.5 ]
  Show Outcome Measure 2

3.  Secondary:   Time to Prostate-Specific Antigen (PSA) Progression   [ Time Frame: Maximum up to Month 30.5 ]
  Show Outcome Measure 3

4.  Secondary:   Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment   [ Time Frame: End of Cycle 3 (Approximately Month 3) ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
These results are up to clinical cutoff 31 December 2013 when all enrolled subjects either completed 6 cycles of treatment or withdrew from study prior to end of cycle 6. Primary endpoint results are complete.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Strategic Lead Oncology Tas
Organization: Janssen Services, LLC
e-mail: ClinicalTrialDisclosure@its.jnj.com



Responsible Party: Janssen Biotech, Inc.
ClinicalTrials.gov Identifier: NCT01314118     History of Changes
Other Study ID Numbers: CR017932
Protocol 212082PCR2005 ( Other Identifier: Janssen Biotech Inc. )
Study First Received: March 4, 2011
Results First Received: December 24, 2014
Last Updated: July 20, 2017